This is a working overview of Research chemical, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-22 and is reviewed periodically as new material appears.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
| Property | Value | Notes |
|---|---|---|
| IUPAC name | {4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]phenoxy}acetic acid | Systematic name for GW501516 |
| CAS Registry Number | 317318-70-0 | Unique identifier for the parent compound |
| Molecular formula | C21H18F3NO3S2 | Includes carbon, hydrogen, fluorine, nitrogen, oxygen, and sulfur |
| Molecular weight | 453.5 g/mol | Approximate value for the neutral form |
| Appearance | White to off-white powder | Typical description for purified laboratory material |
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
The family then mentioned how Lashay had been tested for Rumination's via a M spike testing, which is testing the pressure at the lower esophageal sphincter, with results that are strongly suggestive of Rumination's. With this information, the family had a very strong denial in the fact that Lashay might have a chronic illness with no treatment instead of just a simple parasitic infection.
Members of the parliament of the Free State would be required to take an oath of allegiance to the Constitution of the Free State and to declare that they would be "faithful" to the king (a modification of the oath taken in other dominions). The Second Dáil ratified the Treaty on 7 January 1922, causing a split in the republican movement. A Provisional Government was formed, with Michael Collins as chairman. The Free State was established on 6 December 1922, and the Provisional Government became the Executive Council of the Irish Free State, headed by W. T. Cosgrave as President of the Executive Council. The following day, the Commons and the Senate of Northern Ireland passed resolutions "for the express purpose of opting out of the Free State". Two days after the founding of the Irish Free State, anti-Treaty IRA members opened fire on Seán Hales and Pádraic Ó Máille, both Teachtaí Dála (TDs), as they were leaving the Dáil. Hales was killed, while Ó Máille was seriously wounded. On 8 December 1922, four imprisoned leaders of the anti-treaty IRA (Liam Mellows, Rory O'Connor, Joe McKelvey and Dick Barrett) were executed in retaliation for the killing of Hales.
==== Classical mechanics ==== Classical models of electrostatic properties of electrons in quantum dots are similar in nature to the Thomson problem of optimally distributing electrons on a unit sphere. The classical electrostatic treatment of electrons confined to spherical quantum dots is similar to their treatment in the Thomson, or plum pudding model, of the atom. The classical treatment of both two-dimensional and three-dimensional quantum dots exhibit electron shell-filling behavior. A "periodic table of classical artificial atoms" has been described for two-dimensional quantum dots. As well, several connections have been reported between the three-dimensional Thomson problem and electron shell-filling patterns found in naturally occurring atoms found throughout the periodic table. This latter work originated in classical electrostatic modeling of electrons in a spherical quantum dot represented by an ideal dielectric sphere.
Sources: en.wikipedia.org
Gamma-Dynacare Medical Laboratories is a Canadian medical laboratory services company based in Brampton, Ontario, Canada. Dynacare operates laboratories in Brampton, Bowmanville, London, Ottawa, Thunder Bay, Pointe-Claire, Laval, and Winnipeg. In addition to the main laboratories Dynacare operates patient services centers throughout Ontario, Quebec, Manitoba, Saskatchewan, Alberta and British Columbia. Dynacare is an operational partnership founded in 1997 as Gamma-Dynacare between: Dynacare Laboratories; Gamma North Peel Partnership Inc.; and Bio-Science Laboratory (Ontario) Limited. In 2002 Dynacare Laboratories (one of the Dynacare partners) was acquired by LabCorp for $480-million (U.S.) while also assuming Dynacare debt worth $205-million. In 2015, it rebranded itself back to Dynacare. In 2011 Dynacare acquired the medical laboratory division of Warnex Inc. (TSX:WNX) for $7.5 Million. In 2023 Dynacare acquired the medical laboratories in British Columbia known as Valley Medical Laboratories. This increased the Dynacare presence in British Columbia by adding about 12 locations in Kelowna and throughout the Okanagan Valley.
1994 Malaysian football scandal 1999 Chinese football match-fixing scandal 2001 Chinese football match-fixing scandal 2003–2009 Chinese football match-fixing scandals Apito Dourado (2004) – a match fixing scandal in Portuguese football involving FC Porto, Boavista, and União de Leiria. Bundesliga scandal (2005) – a match fixing scandal in German football centering on disgraced referee Robert Hoyzer. Caso Genoa (2005) Brazilian football match-fixing scandal (2005) – a match fixing scandal involving referees in Brazil. 2006 Calciopoli scandal – a match fixing scandal in Italian football involving several major teams, including three of the country's four qualifiers to the 2006–07 UEFA Champions League. In the Commonwealth of Independent States Cup 2006, the Armenian champion Pyunik refused to play with an Azerbaijani team, PFC Neftchi. The team Pyunik defeated the Ukrainian team Shakhtar Donetsk 3–1 in the quarter-final, when it already knew that in case of victory they would have to play against Neftchi. After the match, they told the referee they would not play against an Azerbaijani team and later that evening left Moscow on an airplane. The Russian Football Union gave Shakhtar Donetsk a technical victory 3–0 so they could play in the half-final instead of Pyunik, but Shakhtar Donetsk declined the offer stating that "[W]e would really want to play in the half-final, but we don't want to get there by any other way then sport".
==== Primeiro Comando da Capital ==== The Primeiro Comando da Capital (PCC) is one of Latin America's largest drug cartels. The organization primarily deals with drugs/arms trafficking, bank robberies and hijacking of armored trucks, as well as illegal gambling and smuggling (especially alcohol, tobacco, gold and timber). It is the biggest faction in Brazil, while also having a significant presence through the rest of South America, Portugal and the United States (mostly through the Brazilian-American community). In recent years, the organization has been reported to operate in many other countries as well, mostly through its alliances with foreign criminal groups (such as 'Ndrangheta in Italy, Group America in Serbia, Tren de Aragua in Venezuela, the Triads in China and the Jalisco Cartel in Mexico) and paramilitary groups (such as the FARC in Colombia and EPP in Paraguay). In recent years, there has even been reported activities of the group in West Africa (mostly aligned with local groups such as the Nigerian Mafia), Eastern Europe (through the Russian and Albanian mafias) and the Middle East (through the Turkish and Lebanese mafias). The group has also been alleged to have ties to the Yakuza in Japan and Hezbollah in Lebanon. PCC was originally founded on August 31, 1993, by eight prisoners at Taubaté Penitentiary, called "Piranhão" ("Big Piranha"), in the state of São Paulo. The group initially got together during a football game, where they founded a team called "Comando Capital" (Capital Command).
Sources: en.wikipedia.org
February 23, 2011 Venezuela Economists expressed concern with regards to Venezuela's economy improving due to instability in the private sector pressured by the socialist government, as José Guerra, former manager at the Central Bank of Venezuela, stated that private investment, accounting for half of Venezuela's GDP, dropped 2.2% in 2010.
Lipedema is a chronic medical condition that is almost exclusively found in women and results in enlargement of both legs due to deposits of fat under the skin. It is characterized by bilateral, symmetrical buildup of fat in the legs, and sometimes arms and lower trunk (includes hips, buttocks, and abdomen). Women of any weight may be affected and the fat is resistant to traditional weight-loss methods like nutritional intervention, exercise, elevation, diuretics or bariatric surgery. The feet/hands are typically spared, presenting with a raised ridge or fold of fat, possibly a "cuff" at the wrists and ankles. In earlier stages, there may be a subtle, raised ridge or fold of fat instead of distinct cuffing and sometimes in the later stages, this increased adipose above the ankle/wrist can cause the appearance of a "cuff". Approximately 50% of people with Lipedema report pain in their fat. Other common symptoms include swelling, feelings of heaviness, and easy bruising in the affected areas. Over time mobility may be reduced, and due to reduced quality of life, people often experience depression. The cause is unknown but is believed to involve genetic and hormonal factors, lipedema onset is typically associated with periods of hormonal flux like puberty, pregnancy, or menopause and it often runs in families. Other conditions that may present similarly include lipohypertrophy, chronic venous insufficiency, and lymphedema. It is commonly misdiagnosed.
=== Combined & global === A different modality is when lysosomes do not just act alone, but in concert with the ER. In this scenario, lysosomes first supply a local, 'trigger' Ca2+ release that then secondarily recruits the IP3Rs or RyRs on the ER by Calcium-induced calcium release (the 'amplifier'). In this mode, lysosomes indirectly evoke a global cytosolic Ca2+ signal (which is actually mediated by the ER). In this way, lysosomal Ca2+ release is amplified, in what is referred to as the 'trigger hypothesis'.
Sources: en.wikipedia.org
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.
It is prohibited by the World Anti-Doping Agency as a hormone and metabolic modulator. Athletes who test positive for GW501516 can face sanctions, including suspensions and loss of results.
Cardarine is a common or trade-style name, while GW501516 is the research code for the same chemical entity. Some sources also use Endurobol or GSK-516. The names refer to the same compound, not distinct drugs.
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.